Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Capital Expenditures (2019 - 2025)

BridgeBio Pharma's Capital Expenditures history spans 7 years, with the latest figure at $33000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 94.99% year-over-year to $33000.0; the TTM value through Dec 2025 reached $1.1 million, up 17.58%, while the annual FY2025 figure was $1.1 million, 17.58% up from the prior year.
  • Capital Expenditures for Q4 2025 was $33000.0 at BridgeBio Pharma, down from $1.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.5 million in Q3 2021 and bottomed at -$10.1 million in Q4 2021.
  • The 5-year median for Capital Expenditures is $498000.0 (2024), against an average of $137000.0.
  • The largest annual shift saw Capital Expenditures skyrocketed 1077.05% in 2021 before it crashed 1885.71% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$10.1 million in 2021, then soared by 60.85% to -$4.0 million in 2022, then soared by 80.59% to -$771000.0 in 2023, then surged by 185.47% to $659000.0 in 2024, then tumbled by 94.99% to $33000.0 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Capital Expenditures are $33000.0 (Q4 2025), $1.1 million (Q3 2025), and -$337000.0 (Q2 2025).